The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Factors influencing the outcomes of NHL patients after ASCT and cyclophosphamide
Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses the report of the EBMT Lymphoma Working Party on the influence of donor type, stem cell source and conditioning regimen on the outcomes of lymphoma patients after haploidentical transplant and cyclophosphamide. Dr Sureda highlights how no donor-related factors were associated with the outcomes of this group, whereas disease status at the time of transplant, type of lymphoma and conditioning regimen did. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
